Table 3.
Estimated Odds Ratios and Confidence Intervals Per Standard Deviation (SD) Increase in lnFGF‐23, Stratified by Chronic Kidney Disease (eGFR <60 mL/min per 1.73 m2)
| eGFR <60 mL/min per 1.73 m2 | eGFR ≥60 mL/min per 1.73 m2 | |||||
|---|---|---|---|---|---|---|
| n=271 | Odds Ratio | P Value | n=616 | Odds Ratio | P Value | |
| No hypertrophy | 87 | 1.0 (ref) | — | 305 | 1.0 (ref) | — |
| Eccentric hypertrophy | 171 | 1.0 (0.7 to 1.4) | 0.93 | 300 | 1.1 (0.9 to 1.4) | 0.37 |
| Concentric hypertrophy | 13 | 2.3 (1.0 to 5.3) | 0.04 | 11 | 1.0 (0.4 to 2.5) | 0.94 |
ACR indicates albumin‐to‐creatinine ratio; BMI, body mass index; eGFR, estimated glomerular filtration rate; FGF‐23, fibroblast growth factor–23; HDL, high‐density lipoprotein; SBP, systolic blood pressure. Adjusted for age, sex, ethnicity, BMI, SBP, diabetes, hypertension, physical activity score, smoking history, total cholesterol, HDL cholesterol, triglycerides, serum phosphorous, serum calcium, ACR, and eGFR. P‐interaction=0.28.